Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes

• Prif Awduron: Katalin Pungor (Awdur), Vasilis P. Bozikas (Awdur), Robin Emsley (Awdur), Pierre-Michel Llorca (Awdur), Srihari Gopal (Awdur), Maju Mathews (Awdur), Annette Wooller (Awdur), Paul Bergmans (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: SAGE Publishing, 2020-12-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Background: Paliperidone palmitate 3-monthly (PP3M) is a second-generation, long-acting injectable antipsychotic formulation indicated for the maintenance treatment of adults with schizophrenia first stabilized with paliperidone palmitate 1-monthly (PP1M). This exploratory post hoc subgroup analysis...